Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression.
Plasma SHBG production by the liver is influenced by its metabolic state, and hepatocyte nuclear factor-4alpha regulates SHBG expression in response to changes in lipogenesis. Peroxisome-proliferator receptors (PPARs) also regulate glucose homeostasis and fatty acid metabolism. The human SHBG promoter contains a PPAR-response element (PPAR-RE), and plasma SHBG levels increase in polycystic ovarian syndrome patients treated with the PPARgamma agonist, rosiglitazone. In addition, plasma SHBG levels are associated with a genetic polymorphism in the PPARgamma-2 coding sequence that alters its transcriptional activity. Therefore, we set out to determine whether PPARgamma influences hepatic production of SHBG by using human HepG2 hepatoblastoma cells as an in vitro model. Surprisingly, treatment of HepG2 cells with rosiglitazone reduced SHBG production and SHBG promoter activity (as assessed in a luciferase reporter gene assay) by 20-25%, whereas the PPARgamma antagonist, GW9662, increased both by 2- to 3-fold. The effects of PPARgamma agonists and antagonists on SHBG promoter activity were substantially diminished when the PPAR-RE in the SHBG promoter was mutated. A PPARgamma small interfering RNA also increased SHBG production by HepG2 cells as well as SHBG promoter activity, and the latter was accentuated by cotreatment with GW9662. Importantly, overexpression of a PPARgamma-2 Pro12 variant in HepG2 cells was more effective at reducing SHBG promoter activity, when compared with PPARgamma-2 Ala12, consistent with its superior PPAR-RE binding activity. We conclude that PPARgamma represses human SHBG expression in liver cells, and that differences in PPARgamma levels and activity contribute directly to variations in plasma SHBG levels.
Selva
David M
DM
Department of Obstetrics & Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z4.
Hammond
Geoffrey L
GL
D000813:Anilides / Q000494:pharmacology; D001665:Binding Sites; D002478:Cells, Cultured; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D050505:Mutant Proteins / Q000502:physiology; D047493:PPAR alpha / Q000819:agonists / Q000502:physiology; D047494:PPAR delta / Q000819:agonists / Q000502:physiology; D047495:PPAR gamma / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D011401:Promoter Regions, Genetic / Q000187:drug effects; D000077154:Rosiglitazone; D012738:Sex Hormone-Binding Globulin / Q000235:genetics* / Q000378:metabolism; D045162:Thiazolidinediones / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology
C457499:2-chloro-5-nitrobenzanilide; D000813:Anilides; D050505:Mutant Proteins; D047493:PPAR alpha; D047494:PPAR delta; D047495:PPAR gamma; D012738:Sex Hormone-Binding Globulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D014212:Tretinoin